Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson's and Alzheimer's Disease at AD/PD(TM) 2026
MWN-AI** Summary
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology firm, recently showcased significant advancements in treatments for Parkinson’s and Alzheimer’s diseases at the AD/PD™ 2026 conference in Copenhagen. Roche presented new findings on prasinezumab, an investigational monoclonal antibody aimed at treating Parkinson's disease, notably revealing data from the PASADENA trial. This data illustrates potential disease modification, showing participants experienced an approximate two-year delay in disease progression compared to modeled predictions. Extended results from the PADOVA study suggest that prasinezumab also effectively slows disease progression in early-stage patients.
Two significant presentations highlighted these findings. Benjamin Ribba discussed a model showing "time saved" as a metric of treatment effects, while Tania Nikolcheva emphasized the sustained benefits seen in early-stage patients receiving prasinezumab alongside symptomatic therapies. Additionally, exploratory analysis indicated the drug's impact on key imaging biomarkers, reinforcing its biological activity.
Bristol Myers Squibb also presented promising data on BMS-986446, a humanized antibody targeting tau proteins linked to Alzheimer’s disease. Initial results from a randomized, double-blind study confirmed the medication's safety and tolerance across diverse ethnic groups, bolstering confidence in its continued development without adjustments for specific populations.
Prothena's partnership with these firms reflects its commitment to addressing neurodegenerative diseases through innovative treatments. Both prasinezumab and BMS-986446 exemplify a deeper understanding of disease mechanisms and may provide novel pathways for managing these debilitating conditions. The significance of these findings emphasizes the urgent need for effective, disease-modifying therapies amid the increasing prevalence of Parkinson's and Alzheimer’s diseases globally.
MWN-AI** Analysis
Prothena Corporation plc (NASDAQ: PRTA) has generated significant investor interest following its presentations at the AD/PD™ 2026 conference showcasing promising new treatments for neurodegenerative diseases. The data supporting prasinezumab for Parkinson's disease demonstrates potential disease-modifying effects, presenting an innovative pathway that diverges from traditional symptomatic treatments. Key findings from the PASADENA trial and PADOVA studies indicate that prasinezumab may substantially delay disease progression, offering prospects of “time saved” in patient outcomes.
Investors should closely monitor the ongoing clinical advancements, as successful Phase III trials could position Prothena as a leader in this therapeutic space. The presented evidence indicates not only biological activity but also strong safety profiles, which are crucial for regulatory approval and market acceptance. Moreover, with over 10 million people affected by Parkinson’s disease globally, the market demand for effective disease-modifying therapies is immense and poised for growth.
Additionally, BMS-986446's presentations on Alzheimer’s disease underscore the critical need for innovative treatments in this area, highlighting the potential for Prothena’s collaborations with established biotech firms like Bristol Myers Squibb. The data presented regarding BMS-986446’s tolerability and pharmacokinetics is reassuring and may positively influence investor sentiment toward both companies as they navigate the complexities of Alzheimer's treatment development.
Currently, with the biotechnology market being inherently volatile, investors should assess their risk tolerance. Prothena’s strategic positioning and advanced pipeline may offer compelling long-term growth opportunities, particularly if the forthcoming clinical trial results continue to substantiate the efficacy of their therapies. Investments in Prothena could be a tactical addition to diversified healthcare portfolios aiming for exposure in groundbreaking biotech ventures.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced partner presentations on clinical updates from prasinezumab for the treatment of Parkinson’s disease and BMS-986446 for the treatment of Alzheimer’s disease at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2026) in Copenhagen, Denmark, and online.
Roche Presentations on Prasinezumab for the Potential Treatment of Parkinson’s Disease
Industry Symposium – Pathways to Progress: Exploring Innovations in AD and PD for Future Practice
- Chair: Malú G. Tansey, Ph.D., Indiana University School of Medicine Stark Neuroscience Institute
- Date: Tuesday March 17, 2026
This symposium reviewed the evolving understanding of the molecular pathophysiology and disease heterogeneity across Alzheimer's disease (AD) and Parkinson's disease (PD). Explored current and emerging treatment pathways, e.g. alpha-synuclein, amyloid-beta and neuroinflammation; including diagnostics, biomarkers and therapeutics. Considered how the advancing understanding of AD and PD informs innovative clinical development approaches and clinical practice.
Oral Presentation – Modeling Parkinson’s Disease Progression to Quantify Long-Term Treatment Effects via the Concept of ‘Time Saved’
- Presenter: Benjamin Ribba, Roche
- Date: Thursday March 19, 2026
The comparison of PASADENA open-label extension (OLE) data with PPMI-based model predictions supports potential disease-modifying efficacy with an estimated two years of ‘time saved’ providing an intuitive measure of long-term benefit. The observed PASADENA OLE outcomes consistently deviated from the model-predicted progression, suggesting a sustained treatment effect. On average, participants were approximately two years less advanced in disease severity five years after the start of the trial compared to the virtual comparator.
Oral Presentation – Prasinezumab in Early-Stage Parkinson’s Disease: Additional Data from the PADOVA Study
- Presenter: Tania Nikolcheva, M.D., Ph.D., Roche
- Date: Saturday March 21, 2026
Longer term data from the PADOVA OLE study in early-stage PD showed a sustained effect of prasinezumab in slowing Parkinson’s progression on top of effective symptomatic therapies. The totality of the evidence suggests a possible clinical benefit of prasinezumab and informed the initiation of the Phase III PARAISO study.
Poster Presentation – Prasinezumab’s Impact on Neuromelanin- and Iron-Sensitive MRI Biomarkers in Parkinson’s Disease: Findings from the PADOVA Phase IIb Study
Exploratory biomarker analysis of PADOVA suggests that prasinezumab is biologically active. This is supported by imaging biomarkers crucial to PD pathology, showing a slowing in the progressive loss of neuromelanin signal in substania nigra pars compacta and reduced iron accumulation in the putamen.
Poster Presentation – Sustained Effect on Prasinezumab on Parkinson’s Disease Motor Progression in the Open-Label Extension of the PASADENA Trial, 5-Year Update
At Year 5, the combined PASADENA arm (delayed- and early-start groups) showed less disease progression compared to the PPMI cohort. This lower progression was observed across multiple measures.
Poster Presentation – Digital Health Technology Detects Group Differences in Practically-Defined OFF L-DOPA State: Results of PADOVA Phase IIb Study of Prasinezumab
Post-hoc Digital Health Technology analyses showed consistent trends favoring prasinezumab in digital data collected in the practically-defined OFF L-DOPA state, in line with the PASADENA Phase 2a Simple Sum digital finding and clinical PADOVA readout.
Bristol Myers Squibb Presentation on BMS-986446 for the Potential Treatment of Alzheimer’s Disease
Oral Presentation – Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BMS-986446 in Healthy Participants, Including Those of Japanese Ethnicity
- Presenter: Ilena George, M.D., Bristol Myers Squibb
- Date: Saturday March 21, 2026
Single-dose BMS-986446 was safe and well tolerated in all participants, including those of Japanese ethnicity. Plasma exposure of BMS-986446 increased dose proportionally. No anti-drug antibodies were detected. These results support BMS-986446 dosing in ongoing clinical studies without adjustments for Japanese ethnicity.
About Prasinezumab
Prasinezumab is an investigational monoclonal antibody designed to bind aggregated alpha-synuclein and thereby reduce neuronal toxicity. By reducing the build-up of alpha-synuclein protein in the brain, prasinezumab can potentially prevent further accumulation and spreading between cells, which may slow progression of the disease.
About Parkinson’s Disease
Parkinson’s disease is a chronic, progressive and debilitating neurodegenerative disease characterized by the gradual loss of neurons that make dopamine and other nerve cells. Today, Parkinson’s disease affects over 10 million people worldwide. The prevalence of Parkinson’s disease is increasing, and it has become one of the fastest-growing neurological disorders. Currently, symptomatic treatments that effectively alleviate motor symptoms are available. However, no therapies slow down or stop the clinical progression of Parkinson’s disease.
About BMS-986446
BMS-986446 is a humanized monoclonal antibody that targets multiple domains of the microtubule binding region of tau, a highly pathogenic tau fragment associated with neurofibrillary tangle formation and cognitive decline in Alzheimer’s disease. BMS-986446 binds to specific regions of the tau protein (R1–R3 within the microtubule-binding domain) to stop cell-to-cell spread of tau and tau uptake into cells. It also activates microglia—the brain’s immune cells—through its Fc receptor function, promoting the clearance of tau via phagocytosis.
About Alzheimer’s Disease
Alzheimer’s disease is a progressive, multifaceted and devastating neurodegenerative disease and the most common type of dementia in adults. Changes in the brain disrupt communication between neurons, impacting memory, cognition and behavior. As a result, Alzheimer’s disease has a significant impact on the day-to-day lives of those it directly affects, as well as on their families, caregivers and friends, resulting in considerable shifts in interpersonal relationships. There remains a critical need for disease-modifying therapies that can slow or delay the progression of Alzheimer’s disease as well as therapies that manage and ease neurobehavioral symptoms.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including Parkinson’s disease, ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, Amyotrophic lateral sclerosis (ALS) and a number of other neurodegenerative diseases. Prothena is developing and applying CYTOPE ® , a novel technology that incorporates a cell-internalizing domain to drive efficient cytosolic delivery with highly specific macromolecular effectors. For more information, please visit the Company’s website at www.prothena.com and follow the Company on X (formerly Twitter) @ProthenaCorp.
Forward-Looking Statements
This press release contains forward-looking statements. These statements relate to, among other things, the treatment potential, designs, proposed mechanisms of action, and potential administration of prasinezumab and BMS-986446; and the continued advancement of our preclinical and clinical pipeline, including the potential and advancement of CYTOPE. These statements are based on estimates, projections and assumptions that may prove not to be accurate, and actual results could differ materially from those anticipated due to known and unknown risks, uncertainties and other factors, as well as those described in the “Risk Factors” sections of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 27, 2026, and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the SEC. We undertake no obligation to update publicly any forward-looking statements contained in this press release as a result of new information, future events, or changes in our expectations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260321254343/en/
Mark Johnson, CFA
Senior Vice President, Head of Investor Relations and Corporate Communications
650-837-8550
IR@prothena.com
Media@prothena.com
FAQ**
What are the anticipated outcomes for Prothena Corporation plc PRTA based on recent presentations regarding prasinezumab's efficacy in slowing Parkinson’s disease progression presented at AD/PD™ 2026?
How might the clinical updates from Prothena Corporation plc PRTA's partner presentations impact investor sentiment and market performance for the company in the coming months?
Can you elaborate on the potential implications of the exploratory biomarker analyses from the PADOVA study on Prothena Corporation plc PRTA's future development strategies for prasinezumab?
In light of the promising results from BMS-9864presentations, how does Prothena Corporation plc PRTA plan to differentiate its pipeline strategies in the competitive landscape of Alzheimer's disease treatments?
**MWN-AI FAQ is based on asking OpenAI questions about Prothena Corporation plc (NASDAQ: PRTA).
NASDAQ: PRTA
PRTA Trading
2.35% G/L:
$10 Last:
148,858 Volume:
$9.84 Open:
